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prior to transplantation induced down-regulation of the costimu-
latory molecules CD40, CD80 and CD86 and MHC class II on
recipient APCs and enhanced the protective statin effect when
donor and recipient were treated (survival AT vs PBS, p0.0012).
Induction of the Th-2 cytokine proﬁle was still permissive for in
vivo graft vs leukemia effects by cytolytic effector function of
CD8 T cells against A20 B-cell lymphoma cells as assessed by
bioluminescence imaging, histology and survival. In vitro CD8 T
cells derived from AT treated animals displayed equal cytolytic
activity against Yac1 T-cell lymphoma cells as compared to T cells
derived from PBS treated animals. Mechanistically we identiﬁed a
role for the STAT-6 pathway in statin induced Th-2 induction as
aGvHD protection was partially reversed with STAT-6-/- donors.
Since L-mevalonate produced by the HMG-CoA reductase is the
precursor of non steroidal isoprenoid compounds, such as farnesyl
and geranylgeranyl pyrophosphate, the statin impact on prenyla-
tion status of critical signaling proteins in alloreactive T cells was
determined. In vitro AT treatment reduced the levels of RAP-1,
RhoB and Ras prenylation in allo-antigen exposed T cells and
abrogated expression of T-bet which is critical for Th1 induction.
We conclude that type II statins have signiﬁcant protective impact
on aGvHD lethality by Th-2 cytokine induction and inhibition of
an uncontrolled Th-1 response, without reduction of GvL activity
which is of great clinical relevance given the widespread use and
well deﬁned toxicity proﬁle of these agents.
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Cord blood is an alternative stem cell source for patients, but
single cord blood units (CBU) may not contain sufﬁcient cell dose
for cord blood transplantation of adults. Double cord blood trans-
plantation (DCBT) has been used to increase the cell dose, but the
majority of reported patients have been Caucasian. We conducted
a retrospective analysis of 43 consecutive DCBT recipients who
received at least one cord blood unit from the StemCyte cord
blood banks. The median age was 21 years (range 1-59) and the
median weight was 59 kg (range 11-112). Diagnoses were: 14
AML, 9 ALL, 6 CML, 5 Thalassemia, 2 Myelodysplasia, 1 lym-
phoma, 1 aplastic anemia and 5 others. 54% were advanced risk,
26% standard risk, and 20% unknown risk status for the leukemia/
lymphoma/MDS cases. Sixty seven percent of the recipients were
non-Caucasian&em;15 patients were Asian, 14 Caucasian, 4 Native
American, 3 Hispanic, 3 African American, 1 mixed race and 3
unknown. Patients were treated with a variety of conditioning
regimens (28% reduced intensity) at 21 international centers over
4 continents. 19 patients received 2 plasma depleted cord blood
units. Cord unit characteristics were as follows: median pre-freeze
TNC dose 3.4  107/kg, median pre-freeze CD34 dose 1.1 
105/kg. The median time to neutrophil (ANC500) engraftment
was 22 days and the median time to platelet 20K and 50K engraft-
ment were 45 days and 62 days respectively. Kaplan-Meier esti-
mates of 1-year transplant related mortality, overall survival, and
disease free survival were 37%, 49%, and 44 % respectively.
Causes of death include infection (33%), multi-organ failure
(21%), relapse (17%), GvHD (0%), and other (29%). Engraftment
correlated with cell dose and disease risk status in univariate anal-
ysis. In conclusion, 1) Double cord blood transplantation can be
performed effectively in a racially diverse patient population, 2)
Plasma depleted cord blood units can be used safely, 3) Cell counts
remain important for engraftment even with the use of 2 cord
blood units.
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Umbilical cord blood (UCB) is an alternative for patients without
related or unrelated donors. Single-unit UCB transplantation in
adults is associated with high transplant related mortality, largely due
to delayed engraftment and infection, so we studied the value of
double unit umbilical cord blood (DUCB) transplantation.Methods:
Reduced-intensity conditioning consisted of ﬂudarabine 30mg/m2 x 6
days, melphalan 100mg/m2 x 1 day, and rabbit ATG 1.5 mg/kg x 4
days. DUCB units were 4/6 HLA-A, B, DR1 matched with each
other and the recipient, and contained a minimum combined dose of
3.7  107 TNC/kg (pre-cryopreservation). GVHD prophylaxis con-
sisted of tacrolimus (serum conc. 5-10 ng/ml) and sirolimus (serum
conc. 3-12 ng/ml), which is effective in PBSC transplantation. Re-
sults: 18 patients (median age 48.5 years, range 19-64) with100 day
follow-up are reported. Diagnoses include NHL(6), AML(5),
MDS(3), HD(3), and CML(1). The total cell doses infused were
4.23 107 TNC/kg (range 3.51–6.74 107) and 2.11 105 CD34
cells/kg (range 0.48–5.67 105). Subjects engrafted neutrophils at 22
(median, range 15–75) and platelets at 46 (median, range 24-69) days
from transplantation. Two subjects did not attain platelet transfusion
independence and there was 1 late graft failure. 100-day treatment-
related mortality was 16.7%. 3 patients developed Gr II-IV acute
GVHD (2 Gr. II and 1 Gr. III) and 2 patients developed chronic
GVHD at a median of 30 and 203 days from transplantation respec-
tively. The median follow up is 6.5 months (range 3-12 months) and
overall survival at 1 year is 64.3%. Causes of death include sepsis(4),
relapse(1), and EBV-associated PTLD(1). Chimerism analysis (n14)
at day 30 revealed complete single cord chimerism in 3, mixed cord
chimerism in 10, and persistent host hematopoiesis with single or
double cord chimerism in 1. By day 100, 5/9 patients demonstrated
complete single cord chimerism and 3/9 demonstrated persistent
double cord chimerism. Conclusions: This study demonstrates ex-
cellent engraftment after DUCB transplantation in adult recipients
after a reduced-intensity conditioning regimen. Using sirolimus and
tacrolimus as GVHD prophylaxis, the risk of acute and chronic
GVHD is low when compared to our prior experience with cyclo-
sporine and MMF, and survival is comparable to other unrelated
donor cohorts. Long-term follow-up on an expanded patient cohort
will be presented at ASBMT.
338
EFFECT OF CD3 CELL DOSE ON OUTCOME IN PATIENTS AFTER
CONDITIONING INCLUDING ANTITHYMOCYTE GLOBULIN FOLLOWED
BY UN-MANIPULATED HLA-MISMATCHED/HAPLOIDENTICAL BLOOD
AND MARROW TRANSPLANTATION
Dong, L.1,2, Wu, T.1,2, Lu, D.-P.1,2, Zhang, M.-J.3, Chen, H.1,2,
Gao, Z.-Y.1,2, Han, W.1, Zhang, Y.-C.1,2, Wang, J.-B.2, Liu, Y.-R.1
Poster Session II122
